Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Core Insights - Editas Medicine, Inc. is set to present a transformative LDL-cholesterol-lowering in vivo CRISPR gene editing medicine at the European Society of Gene and Cell Therapy (ESGCT) Congress in Seville, Spain from October 7-10, 2025 [1][2] Company Overview - Editas Medicine is a pioneering gene editing company focused on developing transformative in vivo medicines for serious diseases using CRISPR technology [4] - The company holds exclusive licenses for the Cas12a and Cas9 patent estates from the Broad Institute and Harvard University for human medicines [4] Upcoming Events - The oral presentation at ESGCT will take place on October 9, 2025, at 5:00 p.m. CEST, with the final abstract number OR069 [2] - Management will also participate in investor conferences in October, including a virtual fireside chat on October 14 and a panel discussion on October 21 in New York [3][5]